| Literature DB >> 27780773 |
Gareth Prosser1, Julius Brandenburg2, Norbert Reiling3, Clifton Earl Barry4, Robert J Wilkinson5, Katalin A Wilkinson6.
Abstract
Mycobacterium tuberculosis is a facultative anaerobe and its characteristic pathological hallmark, the granuloma, exhibits hypoxia in humans and in most experimental models. Thus the host and bacillary adaptation to hypoxia is of central importance in understanding pathogenesis and thereby to derive new drug treatments and vaccines.Entities:
Keywords: Antigens; Hypoxia; Lipid droplets; Macrophage; T cells; Tuberculosis
Mesh:
Year: 2016 PMID: 27780773 PMCID: PMC5335906 DOI: 10.1016/j.micinf.2016.10.001
Source DB: PubMed Journal: Microbes Infect ISSN: 1286-4579 Impact factor: 2.700
Fig. 1The M. tuberculosis response to hypoxia.
The top cell depicts the status of several systems involved in key features of the hypoxic response including the status of the DosS/R regulon (off with bound molecular oxygen on DosS in red). The TCA cycle operating normally with glycolytic and lipolytic precursors and components of the terminal electron transport chain operating through the Cytochrome C oxidase (CCO) system and the NADH oxidase Nuo. The bottom cell represents the status of these same systems under hypoxic conditions. DosS has phosphorylated DosR which transcriptionally engages the “DosR” regulon. The TCA cycle operates in a bifurcated cycle through the glyoxylate shunt to reoxidize NADH coupled to the secretion of succinate and intracellular inclusions of triacylglycerols (TAG) accumulate. Reduction of NADH also occurs through the Cytochrome B/D oxidase (CBD) and Ndh which do not pump protons.
Fig. 2The cellular response to hypoxia.
Left panel: Schematic representation of a human granuloma with central necrosis. It is characterized by a decreasing O2 tension when getting into the center of a granuloma. Necrotic granulomas are characterized by an outer lymphocyte cuff of T and B cells and a macrophage-rich mid region that surrounds an amorph area of caseum in the center. In these characteristic lesions, mycobacteria often reside within necrotic tissue that has no obvious supply of oxygen. Right panel: Graphic illustration of the M. tuberculosis macrophage interaction in normoxia and hypoxia. Infection of macrophages with Mtb leads to a wide array of cellular responses, most of which have been studied under normoxia. Virulent mycobacteria have developed mechanisms operative in infected cells, which allow bacillary replication and persistence by fine-tuning pro- and anti-inflammatory activity. Hypoxic conditions lead to a significnant increase of antimycobacterial effector functions, many of which are significantly enhanced by HIF-1 alpha. This hypoxia-mediated control of Mtb replication is at the same time associated with a significant metabolic reprogramming of its host cell characterized by a shift from oxidative toward glycolytic metabolism. Exposure to hypoxia but also to conserved microbial structures decreased the rate of beta-oxidation, whereas the accumulation of triglycerides increased inside the host cell. This metabolic shift leading to lipid droplet formation is presumably exploited by Mtb. Lipid-laden macrophages are found inside the hypoxic environment of the granuloma and are thought to provide a lipid-rich microenvironment for Mtb, thereby allowing it to adapt to an intracellular lifestyle of non-replicating persistence (NRP) in which it is largely resistant to known bactericidal mechanisms of macrophages and many antimicrobials.
Studies investigating the human immune response to ‘latency antigens’.
| First author and year published | Antigens evaluated | Antigen formulations tested | Numbers studied (human/mouse) | Main findings |
|---|---|---|---|---|
| Leyten et al., 2006 | DosR induced: 25 (selected the most strongly expressed proteins of the DosR regulon; first reference to ‘latency antigens’) | Recombinant proteins | TB patients on treatment (n = 11), after treatment (cured TB, n = 9), TST + LTBI n = 23, uninfected healthy controls n = 21, all recruited in The Netherlands. | Latently infected individuals recognized more latency antigens (specifically Rv1733c, Rv2029c, Rv2627c and Rv2628), compared to TB patients, who responded more strongly to CFP-10. These data suggest immune responses against latency antigens may contribute to controlling latent Mtb infection. |
| Schuck et al., 2009 | Immunodominant: 7 | Recombinant proteins | Patients with active TB (aTB, n = 20) and controls with LTBI (n = 22), recruited in Germany | Significantly higher T-cell responses to 7/35 antigens tested in LTBI. T cells specific for Rv3407 were exclusively detected in LTBI. |
| Black et al., 2009 | Immunodominant: 7 | Recombinant proteins | Healthy household contacts (n = 131) recruited from 3 sites (South Africa, Uganda, The Gambia) | Rv1733c was the most commonly recognized DosR regulated antigen. |
| Gideon et al., 2010 | Immunodominant: 3 | Overlapping synthetic peptides in pools of max 13 peptides per pool. Individual peptides for Rv1986. | Patients with active TB (n = 20), LTBI (n = 29), HIV infected LTBI (n = 19, sampled longitudinally after starting ART), recruited in South Africa. | This study evaluated the antigen specific IL-2 response in parallel with the IFN-gamma response. IFN-gamma responses to the RD11 proteins were inferior compared to the immunodominant molecules, in both aTB and LTBI groups. A strong IL-2 recall response to Rv1986 was found in LTBI. |
| Reece et al., 2011 | Rv2659c, Rv3407 and Rv1733c, expressed by the recombinant rBCGΔureC::hly vaccine | N/A (Recombinant vaccines were tested) | Mice vaccinated and challenged with MTB Beijing/W isolate | Latency associated antigens expressed in a recombinant vaccine can improve long-term protection against |
| Chegou et al., 2012 | 118 infection stage specific antigens, including: immunodominant: 8 | Recombinant proteins (n = 112) and Synthetic peptide pools (n = 8, with 6–13 peptides per pool) | TB patients (n = 23) and healthy household controls (HHC, n = 101), recruited in South Africa | The rpfs (Rv0867c, Rv2389c, Rv2450c, Rv1009, Rv1884c) elicited higher IFN-gamma responses in HHCs compared to TB patients, and could differentiate TB from non-TB with area under the curve (AUC) ranging between 0.72 and 0.8. |
| Gideon et al., 2012 | Immunodominant: 3 | Overlapping synthetic peptides in pools of 7–14 peptides per pool. | Patients with active TB (n = 37), LTBI (n = 40), recruited in South Africa. | Only moderate evidence of infection-stage specific antigen recognition was observed using IFN-gamma and IL-2 ELISpot as readout. Data suggest antigens are similarly targets of the immune response in active TB and LTBI, consistent with the view of TB being a spectrum of infection. |
| Commandeur et al., 2013 | 2170 MTB genes investigated in an unbiased Ag discovery approach for | Recombinant proteins | 4 mouse strains, n = 133 skin test positive control persons and n = 7 TB patients, recruited in The Netherlands and Norway. | The 16 IVE-TB antigens identified were also immunogenic in skin test positive controls, representing TB vaccine candidates and/or TB biomarker antigens. |
| Sutherland et al., 2013 | 21 antigens selected based on the | Recombinant proteins for 19 antigens, and synthetic peptide pools for 2 antigens (Rv2659c and Rv2660). | N = 1247 persons, including 262 HIV-TB+, 454 HIV-LTBI+ and 204 HIV-LTBI-, as well as 77 HIV + TB+, 250 HIV + LTBI + recruited from 5 sites (South Africa, Uganda, The Gambia, Ethiopia, Malawi) | Results combined from all sites indicated HIV uninfected TB patients showed lower responses to latency antigens (Rv0569, Rv1733, Rv1735, Rv1737) and the rpf Rv0867, compared to LTBI persons. |
| Serra-Vidal et al., 2014 | 60 recombinant antigens: | Recombinant proteins | Patients with TB n = 102, LTBI n = 306, healthy controls n = 97, recruited in Spain. | The DosR induced Rv1733 was the most immunogenic and strongly recognized by LTBI compared to TB patients. The Rpf antigen Rv2389 and Rv2435n from the IVE-TB antigens, were also promising LTBI biomarkers in both short term and long term incubation cultures. |
| Torres et al., 2015 | 12 antigens: | Recombinant protein Rv1737 and synthetic peptides for ESAT-6, CFP-10, Rv0081, Rv0569, Rv2031, Rv0288c, Rv3019c, Rv0826, Rv0849, Rv1986, Rv2659c, Rv2693c, Rv1986. | TST + LTBI with documented TB contact (n = 26) and non-documented TB contact (n = 34), followed up longitudinally on INH treatment, recruited in Mexico. | They show an increase in the proportion of IFN-gamma responders to Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein during IPT, which may represent useful markers to evaluate changes associated with treatment of LTBI. |
| Coppola et al., 2015 | Evaluation of Rv1733c (as the most promising candidate from the above studies) as a potential vaccine candidate | Recombinant protein Rv1733 and synthetic peptides (p57-84 and HLA-DR3 restricted p63-77) | HLA-DR3 transgenic mice immunized, and infected with H37Rv. | Strong T cell and antibody responses detected, Rv1733 a promising vaccine candidate, even in the form of synthetic peptides. |
| Arroyo et al., 2016 | 6 antigens: | Recombinant proteins | Contacts of recently diagnosed TB patients (n = 31), and n = 30 long term LTBI (followed for 5–7 years), recruited in Colombia. | Found significant T cell response to the DosR and Rpf antigens in the long term LTBI, indicating a persistent immune response. |
LTBI: latent tuberculosis infection; ART: antiretroviral treatment; TST: tuberculin skin test; RD11: region of deletion 11; IVE: in vivo expressed; EHR: Extended hypoxic response; INH: isoniazid.